Assessment and management of high-risk pregnancies in women with thrombophilia

Blood Reviews

Volumn 23, Issue 4, 2009, Pages 143-147

  Sarig, Galit ^a   Vidergor, Guy ^a   Brenner, Benjamin ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Anti Xa; Gestational vascular complications; LMWH; Pregnancy complications; Pregnancy loss; Thrombophilia

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 5 LEIDEN; ENOXAPARIN; FIBRIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PROTHROMBIN;

ANTICOAGULATION; ARTICLE; BLEEDING; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FETUS WASTAGE; GENE MUTATION; HEART VALVE PROSTHESIS; HEPARIN INDUCED THROMBOCYTOPENIA; HIGH RISK PREGNANCY; HUMAN; HYPERCOAGULABILITY; INJECTION SITE REACTION; INTRAUTERINE GROWTH RETARDATION; LUNG EMBOLISM; OSTEOPOROSIS; POSTPARTUM HEMORRHAGE; PREGNANCY COMPLICATION; PREGNANCY OUTCOME; PRIORITY JOURNAL; PROTEIN S DEFICIENCY; RISK FACTOR; SCORING SYSTEM; SKIN ALLERGY; SPONTANEOUS ABORTION; THROMBOCYTOPENIA; THROMBOPHILIA; THROMBOSIS PREVENTION; VALIDATION STUDY; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; FEMALE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MONITORING, PHYSIOLOGIC; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; PREGNANCY, HIGH-RISK; RESEARCH DESIGN; THROMBOPHILIA; THROMBOSIS;

EID: 67349265515     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.blre.2008.11.001     Document Type: Article

References (34)

1. Brenner B., and Blumenfeld Z. Thrombophilia and fetal loss. Blood Rev 11 (1997) 72-79
2. Bremme K. Haemostasis in normal pregnancy. Women's issues in thrombosis and hemostasis (2002), Martin Dunitz Ltd., London 151-165
3. Rai R., and Regan L. Recurrent miscarriage. Lancet 368 (2006) 601-611
4. Kupferminc M.J., Eldor A., Steinman N., et al. Increased frequency of genetic thrombophilia in women with complications of pregnancy. New Engl J Med 340 (1999) 9-13
5. Sarig G., Younis J.S., Hoffman R., et al. Thrombophilia is common in women with idiopathic pregnancy loss and is associated with late pregnancy wastage. Fertil Steril 77 (2002) 342-347
6. Sanson B.J., Friederich P.W., Simioni P., et al. The risk of abortion and stillbirth in antithrombin-, protein C-, and protein S-deficient women. Thromb Haemost 75 (1996) 387-388
7. Meinardi J.R., Middeldorp S., de Kam P.J., et al. Increased risk for fetal loss in carriers of the factor V Leiden mutation. Ann Intern Med 130 (1999) 736-739
8. Robertson L., Wu O., Langhorne P., et al. The thrombosis: risk and economic assessment of thrombophilia screening (TREATS) study. Thrombophilia in pregnancy: a systematic review. Br J Haematol 132 (2006) 171-196
9. Ginsberg J.S., Brill-Edwards P., Johnston M., et al. Relationship of antiphospholipid antibodies to pregnancy loss in patients with systemic lupus erythematosus: a cross-sectional study. Blood 80 (1992) 859-862
10. Sebire N.J., Regan L., and Rai R. Biology and pathology of the placenta in relation to antiphospholipid antibody-associated pregnancy failure. Lupus 11 (2002) 641-643
11. Rai R., and Regan L. Obstetric complications of antiphospholipid antibodies. Curr Opin Obstet Gynecol 9 (1997) 387-390
12. Kist W.J., Janssen N.G., Kalk J.J., et al. Thrombophilias and adverse pregnancy outcome - A confounded problem!. Thromb Haemost 99 (2008) 77-85
13. Brenner B., Hoffman R., Blumenfeld Z., et al. Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin. Thromb Haemost 83 (2000) 693-697
14. Carp H., Dolitzky M., and Inbal A. Thromboprophylaxis improves the live birth rate in women with consecutive recurrent miscarriages and hereditary thrombophilia. J Thromb Haemost 1 (2003) 433-438
15. Gris J.C., Mercier E., Quere I., et al. Low-molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder. Blood 103 (2004) 3695-3699
16. Brenner B., Hoffman R., Carp H., et al. LIVE-ENOX investigators. Efficacy and safety of two doses of enoxaparin in women with thrombophilia and recurrent pregnancy loss: the LIVEENOX study. J Thromb Haemost 3 (2005) 227-229
17. Rey E., Kahn S.R., David M., et al. Thrombophilic disorders and fetal loss: a meta-analysis. Lancet 361 (2003) 901-908
18. Martinelli I., Taioli E., Cetin I., et al. Mutations in coagulation factors in women with unexplained late fetal loss. New Engl J Med 343 (2000) 1015-1018
19. Bates S.M., Greer I.A., Pabinger I., et al. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians evidence-based clinical practice guidelines (8th ed.). Chest 133 (2008) 844S-886S
20. Kher A., Bauersachs R., and Nielsen J.D. The management of thrombosis in pregnancy: role of low-molecular-weight heparin. Thromb Haemost 97 (2007) 505-513
21. Bates S.M. Management of pregnant women with thrombophilia or a history of venous thromboembolism. Hematol Am Soc Hematol Educ Program (2007) 143-150
22. Hirsh J., and Levine M.N. Low molecular weight heparin. Blood 79 (1992) 1-17
23. Sarig G., Blumenfeld Z., Leiba R., et al. Modulation of systemic hemostatic parameters by enoxaparin during gestation in women with thrombophilia and pregnancy loss. Thromb Haemost 94 (2005) 980-985
24. Vignoli A., Marchetti M., Balducci D., et al. Differential effect of the low-molecular-weight heparin, dalteparin, and unfractionated heparin on microvascular endothelial cell hemostatic properties. Haematologica 91 (2006) 207-214
25. Greer I.A., and Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood 106 (2005) 401-407
26. Lepercq J., Conard J., Borel-Derlon A., et al. Venous thromboembolism during pregnancy: a retrospective of enoxaparin safety in 624 pregnancies. Br J Obstet Gynaecol 108 (2001) 1134-1140
27. Sanson B.J., Lensing A.W., Prins M.H., et al. Safety of low molecular weight heparin in pregnancy: a systemic review. Thromb Haemost 81 (1999) 668-672
28. Brenner B., Bar J., Ellis M., et al. LIVE-ENOX investigators. Effects of enoxaparin on late pregnancy complications and neonatal outcome in women with recurrent pregnancy loss and thrombophilia: results from the LIVE-ENOX study. Fertil Steril 84 (2005) 770-773
29. Laposata M., Green D., Van Cott E.M., et al. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: the clinical use and laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban. Arch Pathol Lab Med 122 9 (1998) 799-807
30. The Columbus Investigators. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. New Engl J Med 337 10 (1997) 657-662
31. Sephton V., Farquharson R.G., Topping J., et al. A longitudinal study of maternal dose response to low molecular weight heparin in pregnancy. Obstet Gynecol 101 (2003) 1307-1311
32. Bounameaux H., and de Moerloose P. Is laboratory monitoring of low-molecular-weight heparin therapy necessary? No. J Thromb Haemost 2 4 (2004) 551-554
33. Gyamfi C., Cohen R., Desancho M.T., et al. Prophylactic dosing adjustment in pregnancy based upon measurements of anti-factor Xa levels. J Matern Fetal Neonatal Med 18 (2005) 329-331
34. Fox N.S., Laughon S.K., Bender S.D., et al. Anti-factor Xa plasma levels in pregnant women receiving low molecular weight heparin thromboprophylaxis. Obstet Gynecol 112 (2008) 884-889